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Bacterial evolution in PCD and 
CF patients follows the same 
mutational steps
Lea M. Sommer1,*, Mikkel Christian Alanin2,*, Rasmus L. Marvig3,4, Kim Gjerum Nielsen5, 
Niels Høiby3,6, Christian von Buchwald2, Søren Molin1,7 & Helle Krogh Johansen1,3
Infections with Pseudomonas aeruginosa increase morbidity in primary ciliary dyskinesia (PCD) and 
cystic fibrosis (CF) patients. Both diseases are associated with a defect of the mucociliary clearance; in 
PCD caused by non-functional cilia, in CF by changed mucus. Whole genome sequencing of P. aeruginosa 
isolates from CF patients has shown that persistence of clonal lineages in the airways is facilitated by 
genetic adaptation. It is unknown whether this also applies to P. aeruginosa airway infections in PCD. 
We compared within-host evolution of P. aeruginosa in PCD and CF patients. P. aeruginosa isolates from 
12 PCD patients were whole genome sequenced and phenotypically characterised. Ten out of 12 PCD 
patients were infected with persisting clone types. We identified convergent evolution in eight genes, 
which are also important for persistent infections in CF airways: genes related to antibiotic resistance, 
quorum sensing, motility, type III secretion and mucoidity. We document phenotypic and genotypic 
parallelism in the evolution of P. aeruginosa across infected patients with different genetic disorders. 
The parallel changes and convergent adaptation and evolution may be caused by similar selective forces 
such as the intensive antibiotic treatment and the inflammatory response, which drive the evolutionary 
processes.
Pseudomonas aeruginosa is an opportunistic pathogen that frequently causes chronic infections in the upper and 
lower airways of primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) patients1–4. Patients are usually colo-
nised in childhood, but despite intensive antibiotic therapy a chronic infection is rarely prevented.
Stasis of respiratory secretions is inevitable in patients with PCD and CF predisposing both patient groups to 
airway infections, inflammations and declining lung function3,5. In healthy people inhaled pathogens are phago-
cytised or entrapped and removed by mucociliary clearance with constant beating of motile cilia. The cilia drive 
the mucus and pathogens out of the airways where they are cleared by coughing, expectoration, or swallowing of 
sputum. However, both PCD and CF are autosomal recessive disorders where the function of airway clearance is 
impaired: either directly in PCD by mutations resulting in structural and functional abnormalities of the cilia6, 
or indirectly in CF by mutations in a chloride ion channel resulting in dehydrated mucus in the airways, thereby 
impairing the ciliary movements7–9.
We hypothesise that if the main selective pressures found in the PCD and CF airways are the host immune 
defence system and the frequent presence of antibiotics, then the adaptation and evolution of P. aeruginosa should 
not differ significantly between the two groups of patients. However, if the main selective pressure is the immedi-
ate environment comprising the structure and composition of the mucus found in the airways, then the adapta-
tion and evolutionary pathways could differ significantly.
Investigations of P. aeruginosa in CF patients have shown how the bacterium can adapt and evolve in the 
CF lung environment via mutational and phenotypic changes10–17. The most important characteristics include 
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overproduction of alginate (mucoidity), slow growth, altered biofilm mode of growth, loss of motility, quorum 
sensing and protease production10,13,18–21. These adaptational changes are to a large degree associated with anti-
biotic treatments, the activity of the immune defence, and specific physico/chemical characteristics of the CF 
mucus. However it is not clear to what degree these factors independently and together impact the adaptation and 
evolution of P. aeruginosa. Similar adaptive and evolutionary investigations have to our knowledge never been 
performed in P. aeruginosa from PCD patients.
In order to understand the adaptation and evolution across the two different diseases of defective mucociliary 
clearance, we whole genome sequenced and phenotypically characterised P. aeruginosa isolates longitudinally 
from PCD airways in order to compare these with the evolutionary processes previously identified in the airways 
of CF patients10,12,18–20,22,23.
Materials and Methods
Patients. We included 12 PCD patients with chronic P. aeruginosa lung infection. Chronic infection was 
based on the frequency of P. aeruginosa positive airway samples in combination with elevated precipitins, as 
defined previously3. All had a definitive PCD diagnosis based on presentation of the characteristic clinical phe-
notype, ciliary ultrastructural defects visualized by electron microscopy, high speed video recordings showing 
abnormal ciliary function and/or a genetic mutation recognized to cause PCD24. All patients were diagnosed and 
treated at the Danish Pediatric Pulmonary Centre and PCD Centre, Rigshospitalet, Copenhagen. Patients are 
followed on a routine basis every three months, where a sputum sample is collected for bacteriological investiga-
tions, and clinical data is recorded as previously outlined25.
PCD bacterial isolates. Isolation and identification of P. aeruginosa from PCD sputum samples was car-
ried out as previously described, independent of the underlying condition26. Antimicrobial susceptibility profiles 
were determined for eight antibiotics: piperacillin + tazobactam, imipenem, aztreonam, ceftazidime, tobramycin, 
colistin, ciprofloxacin, and meropenem.
Thirty-five longitudinal P. aeruginosa isolates were whole genome sequenced, on average 2.9 isolates (range 
2–5) per patient with an average timespan of 2.0 years (range 0.4–3.6) (Fig. 1A).
We also phenotypically analysed 41 longitudinal isolates, on average 3.4 isolates (range 2–6 isolates) per 
patient with an average timespan of 2.4 years (range 0.4–4.8 years) (Fig. 1A,B).
The median age at the PCD diagnosis was 7.4 years (range 0.1–29.4 years). The median age of the patients at 
the time of diagnosis of chronic P. aeruginosa lung infection was 15.5 years (range 9–59 years), and the median 
age at which the first P. aeruginosa isolate was included in this study was 17.5 years (range 10–62 years). The 
median age of the patients when they had their first P. aeruginosa cultured was 12 years (range 4–45 years). The 
median time from first cultured P. aeruginosa isolate to the first analysed isolate was 6 years (range 1–18 years).
Antibiotic treatment of patients. At Rigshospitalet, chronic lung infection with P. aeruginosa is treated 
in the same way in PCD and CF patients3,27. Antibiotic treatment is initiated when a sample from the lower 
Figure 1. Patient and isolate overview. (A) Genotypic characterisation. “First PA (Pseudomonas aeruginosa)” 
shows the year the patients had the first culture of P. aeruginosa. Isolates denoted by “X” were not sequenced.  
(B) Phenotypic characterisation. The phenotypic characteristics are shown for 41 isolates sampled at the same 
time points as indicated by isolates in (A). When phenotypic boxes are close together isolates were sampled 
from the same sputum sample (se legends to Fig. 1A). A grey box indicates a non-characterisable phenotype 
(N/A), white indicates the absense of a phenotype, and coloured boxes indicate the presence of a phenotype.
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airways is positive for a relevant pathogen, even if clinical symptoms are absent. Chronically infected patients 
are treated with a combination of intravenous antibiotic therapy according to susceptibility testing, either with a 
broad-spectrum beta-lactam or a carbapenem in combination with an aminoglycoside, colistin or ciprofloxacin, 
every third month. Between intravenous courses, chronically infected patients are treated with inhalation antibi-
otics and oral quinolones at the discretion of the treating physician.
Genome sequencing and analysis of PCD isolates. Genomic DNA from the 35 P. aeruginosa 
strains was prepared using the Qiagen Blood & Tissue Kit and Nextera XT Sample Preparation kit. It was 
sequenced on an Illumina MiSeq platform generating an average of 1,695,366 150 bp paired end reads (range of 
1,251,910–3,140,054) for each library to yield an estimated average genome coverage of 58.96-fold 
(range of 33.28–84.76-fold). See Supplementary Table S1 for information about genomic coverage depth for indi-
vidual isolates. Sequences were analysed as previously described17.
The identification of genes with significant mutational patterns of convergent evolution was carried out using 
the same principles as in Marvig et al.17 in which the observed distribution of mutations were evaluated in com-
parison with 1,000 iterative scenarios in which mutations were randomly introduced by genetic drift. Briefly, 
all genes were considered separately, and dependent on their specific size genes were more or less likely to be 
mutated, according to the random roulette theory. It is assumed that if all mutations are randomly introduced into 
the genome (i.e. no selection pressure), the size of a gene will determine the number of mutations it will acquire 
by chance. Furthermore, genes had to be mutated in two or more clone types. However, if a gene was only mutated 
in two clone types, a further constraint was added: in the 1,000 iterations the gene must not have been mutated in 
more than 1 clone type at any time.
Phenotypic characterisation. Growth rate analysis. All isolates were incubated directly from freezing 
stock in a 96 well plate with 100 μ l Luria Bertani (LB) broth, leaving the outer wells blank. The plates were incu-
bated at 37 °C in a microtiter plate reader (Holm & Halby, BioTek Instruments Inc., DK-2605, model: ELX808IU) 
with OD (600 nm) readings every 20 minutes until all isolates reached stationary phase. All isolates were assayed 
with a minimum of three replicates and a maximum of seven.
Motility assays were performed on soft agar plates of LB medium (twitching: 1% agar, swimming: 0.3% agar). 
Plates were inoculated from single colonies using sterile toothpicks, positioning the colony at the bottom of the 
plate (twitching) or in the middle of the agar (swimming), both were incubated for 24 hours at 37 °C. The swim-
ming assay was carried out in 96 well microtiter plates: a positive well was indicated by a turbid well, whereas a 
negative was clear. All isolates were assayed with a minimum of three replicates and a maximum of four.
Secreted protease production was assayed using LB agar (1% agar) and 3% (w/vol) skimmed milk. 200 μ l agar 
was added to each well of a 96 well plate. After drying, a hole was made in each well, where 10 μ l supernatant of 
an overnight liquid culture (also grown in LB at 37 °C) was deposited. After 24 h, wells were read as positive if the 
agar had become clear and negative if opaque. All isolates were assayed with a minimum of five replicates and a 
maximum of eight.
Attachment assays (in vitro biofilm) were performed using an overnight culture grown in LB broth at 37 °C. 
The culture was diluted 1:100 and 150 μ l was added to each well in a 96 well plate and a start OD (600 nm) was 
measured. The plates were incubated at 37 °C, 150 rpm for 24 h and end point OD (600 nm) was measured. The 
culture was removed and the plates washed three times in tab water, where after 200 μ l 0.01% crystal violet was 
added to each well. After 20 min at room temperature (RT) the crystal violet was removed and the plates were 
washed three times in tab water. 200 μ l 96% ethanol was added to each well and left for 20 min, 240 rpm at RT, 
where after OD (620 nm) was measured. The outer wells were not used and isolates were run with six replicates 
in each plate (and six blank controls), and this was done a minimum of three times and a maximum of seven for 
each isolate.
Accession numbers. Sequence reads from all P. aeruginosa isolates have been deposited in the Sequence 
Read Archive (SRA) and can be found at: http://www.ebi.ac.uk/ena/data/view/PRJEB12111 under accession 
numbers: ERS1014363-ERS1014397 (Supplementary Table S1).
Ethics. The local ethics committee at the Capital Region of Denmark Region Hovedstaden approved the use of 
the samples: registration number H-4-2015-FSP. All patients have given informed consent. For patients below 18 
years of age, informed consent was obtained from their parents. The study was carried out in accordance with the 
approved guidelines and the University Hospital Rigshospitalet approved the experimental protocol.
Statistics. All statistical analyses were carried out using the program R28, when multiple testing was per-
formed a Bonferroni correction for multiple testing was used (biofilm production).
Results
Phylogeny of the PCD isolates. The genomic analysis identified 14 distinct clone types, of which six have 
previously been identified in CF patients: DK06, DK08, DK19, DK21, DK51, and DK5417. This suggests that there 
is no single clone type, which is responsible for the infections seen in either PCD or CF patients. It has previously 
been documented that clone types can be transmitted between CF patients17,29, and since the Copenhagen CF 
clinic and the Danish PCD Centre are located at close proximity in the hospital it may increase the risk of patients 
being exposed to the same P. aeruginosa clone types. This may be caused either by (1) direct patient-to-patient 
transmission, (2) indirect transmission via common environmental reservoirs or (3) reservoirs at the hospital30,31.
We investigated the possibility of direct patient-to-patient transmission by measuring the genetic distances 
between the earliest isolates sequenced from CF17 and PCD patients with shared clone types, (Supplementary 
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Table S2). In all cases 68 SNPs or more separated the isolates with shared clone types, making a recent transmis-
sion between PCD and CF patients unlikely to have occurred, if it is assumed that the within-patient mutation 
rate of P. aeruginosa is around 2.6 SNPs/year, as found for CF isolates15.
The PCD patients included in this study have previously been shown to be infected with independent clone 
types assessed by Pulsed-field-gel-electrophoresis (PFGE), and 10 out of 12 patients were found to be infected by 
a single primary clone type, whereas two patients (P01 and P06) had a clone type switch during the study period3. 
The whole genome sequencing of the same isolates confirms these observations (Fig. 1A).
Adaptive evolution: Pathoadaptation. P. aeruginosa can be isolated from many environments in water 
and soil and has been shown to be capable of colonizing a variety of hosts. Colonization by P. aeruginosa can lead 
to long-term infections with genetically adapted bacteria, as has been shown specifically for airway infections in 
CF patients. It has been suggested that genes that are repeatedly targeted by mutations are a sign of adaptive evo-
lution, optimising the fitness of the bacteria (pathoadaptive mutations)15–17,32. In CF it appears that bacteria with 
multiple pathoadaptive mutations are more resilient to adverse conditions and more likely to persist in the host15.
To identify pathoadaptive mutations in P. aeruginosa from the PCD patients, we identified genetic variants by 
the comparison of the genomes of isolates within clone types. We identified mutations that had accumulated since 
the earliest isolate, in this case representing the most recent common ancestor (MRCA). This was only possible 
for clone types that were represented in the PCD collection with more than one isolate (11 out of 14 clone types), 
thus excluding the clone types DK06, DK21, and DK54 from this analysis.
In total we found 417 non-synonymous mutations that accumulated in the recent evolutionary history of the 
11 clone types. On the basis of the number of non-synonymous mutations that accumulated in each clone type 
we identified genes relevant for the adaptation to the PCD airways and found genes that had been mutated in 
parallel between clone types. These genes were identified using an extension of a previously described method17. 
The number of non-synonymous mutations accumulated in each clonal lineage was used to estimate the expected 
number of mutations to be found in each individual gene, depending on the size of the gene.
We identified eight genes that were more frequently mutated than would be expected to result from genetic 
drift; these genes were mutated in two to six clone types out of 11 (Fig. 2A, Supplementary Table S3). Our findings 
suggest that parallel non-synonymous mutations in these genes are the result of positive selection for mutations 
in genes undergoing adaptive evolution. Therefore we refer to these as candidate pathoadaptive genes in which 
mutations optimize pathogen fitness.
Of these eight candidate pathoadaptive genes, six have previously been identified as candidate pathoadaptive 
genes in the CF airways (Fig. 2B)15–17. The genes found to be repeatedly mutated in both PCD and CF are: mucA, 
algU, lasR, mexZ, mexS, and mexA. The two genes not identified in candidate pathoadaptive gene lists in previous 
CF studies are pilG and pscP. However, both genes have previously been found mutated in CF populations of P. 
aeruginosa, and although pilG is not identified as pathoadaptive, other pili-processing genes such as pilQ and pilD 
have been listed as such17.
It is important to note that of the eight candidate pathoadaptive genes, three are mex genes. In 20 out of the 35 
isolates we found mutations in one or more of these mex genes.
The mex genes encode efflux pumps that have been found to be important for the resistance towards many 
antibiotics33–35, indicating, like in CF, that a primary selection force is the antibiotic pressure. However, antibiotic 
resistance was uncommon and only observed in five isolates against imipenem and one isolate against ciprofloxacin.
Mutations in mucA and algU are associated with the important hallmark of mucoidity, and have been found 
in CF isolates to be historically contingent17. This led us to investigate whether this is also the case in PCD. Six 
Figure 2. Genes mutated in more clones than would be expected by genetic drift. (A) Overview of the 
number of clones observed to be mutated in each gene, and the enrichment of genes mutated relative to 
expectance (p < 0.0001). (B) Overlap of the genes found to be important for the adaptation of Pseudomonas 
aeruginosa to the PCD airways, and genes found important for the adaptation to CF airways in three other 
studies: Smith (2006)16, Marvig (2013)15, and Marvig (2015)17. It should also be noted, that even though the 
genes lasR and mucA are not on the pathoadaptive gene list of Marvig (2013)15, they were found to have been 
mutated in all isolates; however, the mutations had happened in an ancestor isolate.
www.nature.com/scientificreports/
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isolates were found to carry mutations in one or both genes, and in only one case did we find a mutation in algU 
without finding mutations in mucA (Supplementary Table S4), and in this case it was a silent mutation. The other 
four isolates had mutations in both genes, and only one had a mutation in mucA alone.
Five mucoid clones were identified among the PCD isolates. Four of these have nonsense mutations in mucA, 
mucB, or mucD, all of which have previously been shown to result in mucoid phenotypes21. Additionally, mucA 
and mucD mutations were identified in non-mucoid isolates in the absence of obvious second-site mutations in 
algU, which are often associated with phenotypic reversion to non-mucoidity. It has previously been shown that 
the reversion to a non-mucoid phenotype can be caused by second-site mutations in other genes than algU21, 
which is likely, also the case here.
Adaptive evolution: Phenotypic adaptation. Many studies have shown that CF isolates of P. aeruginosa 
converge towards common phenotypes in relation to slow growth, loss of motility, quorum sensing, and reduced 
in vitro biofilm production of non-mucoid strains36. We therefore tested the phenotypic properties of the PCD 
isolates with regard to mucoidity, protease production (indicator of quorum sensing), swimming and twitching 
motility, generation time, and attachment (i.e. in vitro biofilm formation) (Figs 1B and 3, and Supplementary 
Table S5). We found that none of the longitudinal PCD isolates showed a clear pattern of becoming mucoid, and 
only four out of 12 patients seem to have populations that lose swimming motility and the ability to produce 
protease.
With regard to in vitro biofilm formation we found that the earliest isolates from each patient compared to the 
latest isolates remained equally capable of attachment and biofilm formation, only two patients’ isolates showed 
significant change in this trait, towards an increase in biofilm production (p < 0.01 and R2 > 0.8), Fig. 3. We also 
observed an apparent increase in biofilm formation between isolates from patient P09; nonetheless, the differ-
ence was not statistically significant. This is probably because of the large variance between measurements of the 
replicates of the latest isolate (0.8–1.3). If the highest value (1.3) is removed from the data we reach statistical 
significance of p = 0.005 (with Bonferroni correction for multiple testing), and this is the only value that can be 
removed to reach statistical significance of this difference in biofilm production.
Overall, the generation time did not increase and we found a median generation time of 36 min (range: 
22–104 min, n = 41) similar to wild type PAO1, which we found to have a generation time of 29 min (1.82 
Standard deviation) (Supplementary Table S5). Four of the patients had P. aeruginosa isolates that showed sig-
nificant changes in generation time over the course of infection, two increased (P05 and P12) and two decreased 
(P06 and P07), p < 0.05, R2 > 0.7.
Discussion
The PCD patients investigated in this study have been infected with P. aeruginosa for varying lengths of time, but 
10 out of 12 patients have an infection history more comparable to the recently described cohort of young CF 
patients17 with persistent airway infections (Fig. 1) than to chronically infected older CF patients12.
By genome sequencing 35 and phenotypically characterising 41 P. aeruginosa isolates from PCD patients, we 
have provided a detailed insight in the bacterial evolution within the airways of PCD patients. We have found 
evidence of convergent molecular evolution in eight genes of P. aeruginosa isolates from PCD patients, and strik-
ingly, six of these were also found to be particularly important for the adaptation in CF airways15–17. This is an 
Figure 3. Biofilm production (attachment assay). Bar plot of the biofilm production of the first and last isolate 
from each patient (from Fig. 1A), including PAO1 as control, * p < 0.01 and R2 > 0.75 linear regression with 
Bonferroni correction for multiple testing. Error bars: Standard error of the mean (SEM) (SD/square root (n), 
n = number of samples), numbers in parenthesis below the patient IDs represent the number of years between 
the first and last isolate for each of the patients.
www.nature.com/scientificreports/
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investigation strategy that has been previously reviewed in Marvig et al.37, where four different pathoadaptive gene 
lists were compared and overlaps were identified between the studies. These overlaps were specifically related to 
antibiotic resistance and gene regulation, which was also the case for the six overlapping genes identified in this 
study. One of the pathoadaptive genes identified in our study was lasR, which is associated with transcriptional 
regulation. This was also described by Yang et al., who found this regulatory gene, to be mutated within the first five 
years of colonisation with P. aeruginosa in multiple CF patients38. In addition, the two remaining genes (pscP and 
pilG) were also targeted by mutations in CF isolates17. Thus, parallel changes in the genome sequences probably 
reflect similarities in the selective pressures acting on the P. aeruginosa populations in the airways of the two patient 
groups with different underlying conditions. The finding that the repeated genome changes overlap in PCD and CF 
isolates suggests that the environmental conditions in PCD and CF airways are highly similar. These similarities 
relate in particular to antibiotic therapy as well as to the immune response and impaired mucociliary clearance6–9.
The low number of pathoadaptive mutations relative to what was recently described for young CF patients most 
likely reflects the much lower number of genome sequenced bacterial isolates as well as the relatively short infection 
time with P. aeruginosa that we covered in the PCD patients: 474 CF isolates collected over a median of 4.8 years 
versus 35 PCD isolates collected over a median of 2.4 years17. Interestingly, the obtained results strongly suggest that, 
as is the case in CF patients, many clone types of P. aeruginosa rapidly establish persistent infections in PCD patients, 
and that they accumulate pathoadaptive mutations over time (Figs 1B and 2A). In a small longitudinal study in PCD 
patients39 substantial variability in the bacterial community composition was found between the patients, in contrast 
to the remarkable stability, which was observed for single patients over longer periods of time. This suggests that the 
patients keep the same clone type over time, as also shown by the persistence of clone types seen in this study.
Isolates of P. aeruginosa from older chronically infected CF patients often share a number of phenotypic 
changes such as slow growth, loss of motility and quorum sensing, increased antibiotic resistance and overex-
pression of alginate resulting in a mucoid phenotype on agar plates36. Such phenotypic changes are expected to 
gradually accumulate in bacterial isolates from young CF patients. In the present analysis of phenotypic changes 
in PCD isolates of P. aeruginosa we see a pattern of slow changes of the various tested phenotypes when compared 
with reference strain properties. The phenotypic traits of most of the PCD isolates retained many of the P. aerug-
inosa wild type traits (PAO1), such as being motile, producing proteases, maintaining and in some cases increas-
ing the ability to attach (producing biofilm), remaining susceptible to antibiotics and retaining the growth rate 
(Fig. 1B and Supplementary Table S5)10. One reason that we only see occasional phenotypic adaptation could be 
due to the relatively short sampling period, indicating that the convergence towards a phenotype comparable to 
the isolates from chronically infected CF patients happens much later. Moreover, the occurrence of hyper-mutator 
isolates frequently identified in older CF patients was not observed among the PCD isolates, which is in accord-
ance with the very low frequency identified among isolates obtained from young CF patients17,40.
All together the maintenance of wild-type phenotypic traits in the PCD isolates parallels the modest accumu-
lation of pathoadaptive mutations. It is also obvious that in PCD airways, the bacterial populations are often het-
erogeneous since many different phenotypes were identified within single patients (Fig. 1B). Furthermore, it has 
been shown that PCD patients sometimes clear a chronic P. aeruginosa infection, as a consequence of antibiotic 
treatment3. This resembles the situation in young CF patients where long-term persistent infections in some cases 
may be cleared, but it is in contrast to chronically infected CF patients, where clearance is rarely achieved1,10,15,17. 
Clearance may favour re-colonisation from the sinuses4 or wild type environmental isolates similar to what was 
observed in young CF patients17.
Our results show that P. aeruginosa can establish persistent infections in both CF and PCD patients, with the P. 
aeruginosa population gradually adapting to the airways through various mutations in specific genes. There may 
be differences between the CF and PCD infections with respect to the speed of adaptation, but in general it seems 
that the adaptive processes in the bacterial populations are very similar. This conclusion may support a therapeu-
tic strategy for the PCD patients, which is very similar to the treatment of airway infections in young CF patients 
where 3-week antibiotic courses are initiated when P. aeruginosa is cultured from the airways27.
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